<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2210101-B1" country="EP" doc-number="2210101" kind="B1" date="20140108" family-id="40583340" file-reference-id="299957" date-produced="20180826" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146588187" ucid="EP-2210101-B1"><document-id><country>EP</country><doc-number>2210101</doc-number><kind>B1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-08799234-A" is-representative="NO"><document-id mxw-id="PAPP154850379" load-source="docdb" format="epo"><country>EP</country><doc-number>08799234</doc-number><kind>A</kind><date>20080905</date><lang>EN</lang></document-id><document-id mxw-id="PAPP220294774" load-source="docdb" format="original"><country>EP</country><doc-number>08799234.3</doc-number><date>20080905</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140547293" ucid="US-2008075394-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>2008075394</doc-number><kind>W</kind><date>20080905</date></document-id></priority-claim><priority-claim mxw-id="PPC140548128" ucid="US-97882007-A" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>97882007</doc-number><kind>A</kind><date>20071030</date></document-id></priority-claim></priority-claims><dates-of-public-availability><intention-to-grant-date><date>20130723</date></intention-to-grant-date><search-report-dispatch-date><date>20110228</date></search-report-dispatch-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989324921" load-source="docdb">G01N  33/543       20060101AFI20090527BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL1989627431" load-source="docdb" scheme="CPC">G01N  33/72        20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989636149" load-source="docdb" scheme="CPC">G01N  33/558       20130101 FI20130101BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132369194" lang="DE" load-source="patent-office">VERFAHREN  ZUM NACHWEIS VON OKKULTEM BLUT</invention-title><invention-title mxw-id="PT132369195" lang="EN" load-source="patent-office">METHOD FOR THE DETECTION OF OCCULT BLOOD</invention-title><invention-title mxw-id="PT132369196" lang="FR" load-source="patent-office">MÉTHODE DE DÉTECTION DE SANG OCCULTE</invention-title><citations><non-patent-citations><nplcit><text>"Quick Chaser Occult Blood", 1 January 2009 (2009-01-01), XP055048545, Retrieved from the Internet &lt;URL:http://www.mizuho-m.co.jp/product/obt/e_obt_top.html&gt; [retrieved on 20121227]</text><sources><source mxw-id="PNPL67087857" load-source="docdb" name="EXA"/></sources></nplcit><nplcit><text>LEE E W ET AL: "Differential Diagnosis of Gastrointestinal Bleeding", TECHNIQUES IN VASCULAR AND INTERVENTIONAL RADIOLOGY, XX, XX, vol. 7, no. 3, 1 September 2004 (2004-09-01), pages 112 - 122, XP004880165, ISSN: 1089-2516, DOI: 10.1053/J.TVIR.2004.12.001</text><sources><source mxw-id="PNPL67087858" load-source="docdb" name="EXA"/></sources></nplcit><nplcit><text>LI MING-YONG ET AL: "Application of fecal occult blood detected by transferrin/ hemoglobin gold method", LAB MED CLIN, CN, vol. 7, no. 14, 1 July 2010 (2010-07-01), pages 1 - 5, XP007921904</text><sources><source mxw-id="PNPL67087859" load-source="docdb" name="EXA"/></sources></nplcit><nplcit><text>MICHAEL J BARRY: "PROSTATE-SPECIFIC-ANTIGEN TESTING FOR EARLY DIAGNOSIS OF PROSTATE CANCER", NEW ENGLAND JOURNAL OF MEDICINE, THE, MASSACHUSETTS MEDICAL SOCIETY, WALTHAM, MA, US, vol. 344, no. 18, 3 May 2001 (2001-05-03), pages 1373 - 1377, XP007921903, ISSN: 0028-4793</text><sources><source mxw-id="PNPL67087860" load-source="docdb" name="EXA"/></sources></nplcit><nplcit><text>MIYOSHI H ET AL: "Clinical study of a new fecal occult blood test using a combination assay of hemoglobin and transferrin", GASTROENTEROLOGIA JAPONICA, JAPANESE SOCIETY OF GASTROENTEROLOGY, TOKYO, vol. 26, no. 2, 1 April 1991 (1991-04-01), pages 151 - 156, XP009144251, ISSN: 0435-1339</text><sources><source mxw-id="PNPL67087861" load-source="docdb" name="EXA"/></sources></nplcit><nplcit><text>UCHIDA K ET AL: "Immunochemical detection of human blood in feces", CLINICA CHIMICA ACTA, ELSEVIER BV, AMSTERDAM, NL, vol. 189, no. 3, 31 August 1990 (1990-08-31), pages 267 - 274, XP023396920, ISSN: 0009-8981, [retrieved on 19900831], DOI: 10.1016/0009-8981(90)90308-F</text><sources><source mxw-id="PNPL67087862" load-source="docdb" name="EXA"/></sources></nplcit></non-patent-citations></citations></technical-data><parties><applicants><applicant mxw-id="PPAR919542278" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>WAN JOHN</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR919504284" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>WAN, JOHN</last-name></addressbook></applicant><applicant mxw-id="PPAR919519853" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>WAN ZHIJING</last-name><address><country>CN</country></address></addressbook></applicant><applicant mxw-id="PPAR919527031" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>WAN, ZHIJING</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919513001" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>WAN JOHN</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919541492" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>WAN, JOHN</last-name></addressbook></inventor><inventor mxw-id="PPAR919021941" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>WAN, JOHN</last-name><address><street>1713 Virginia Road</street><city>San Marino, CA 91108</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919509907" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>WAN ZHIJING</last-name><address><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919536007" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>WAN, ZHIJING</last-name></addressbook></inventor><inventor mxw-id="PPAR919021942" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>WAN, ZHIJING</last-name><address><street>A-205 Yihe International Center No. 1 Guanghuaxili Chao Yang District</street><city>Beijing 100020</city><country>CN</country></address></addressbook></inventor></inventors><assignees><assignee mxw-id="PPAR919021944" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Wan, John</last-name><iid>101112031</iid><address><street>1713 Virginia Road</street><city>San Marino, CA 91108</city><country>US</country></address></addressbook></assignee><assignee mxw-id="PPAR919021945" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>Wan, Zhijing</last-name><iid>101112035</iid><address><street>A-205 Yihe International Center No. 1 Guanghuaxili Chao Yang District</street><city>Beijing 100020</city><country>CN</country></address></addressbook></assignee></assignees><agents><agent mxw-id="PPAR919021943" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Lane, Cathal Michael</last-name><suffix>et al</suffix><iid>100043338</iid><address><street>Tomkins &amp; Co. 5 Dartmouth Road</street><city>Dublin 6</city><country>IE</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="US-2008075394-W"><document-id><country>US</country><doc-number>2008075394</doc-number><kind>W</kind><date>20080905</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2009058478-A1"><document-id><country>WO</country><doc-number>2009058478</doc-number><kind>A1</kind><date>20090507</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549890196" load-source="docdb">AT</country><country mxw-id="DS549799596" load-source="docdb">BE</country><country mxw-id="DS549782410" load-source="docdb">BG</country><country mxw-id="DS549783534" load-source="docdb">CH</country><country mxw-id="DS549799609" load-source="docdb">CY</country><country mxw-id="DS549890201" load-source="docdb">CZ</country><country mxw-id="DS549923050" load-source="docdb">DE</country><country mxw-id="DS549799610" load-source="docdb">DK</country><country mxw-id="DS549799611" load-source="docdb">EE</country><country mxw-id="DS549870791" load-source="docdb">ES</country><country mxw-id="DS549782411" load-source="docdb">FI</country><country mxw-id="DS549783535" load-source="docdb">FR</country><country mxw-id="DS549923051" load-source="docdb">GB</country><country mxw-id="DS549799612" load-source="docdb">GR</country><country mxw-id="DS549923052" load-source="docdb">HR</country><country mxw-id="DS549890202" load-source="docdb">HU</country><country mxw-id="DS549783536" load-source="docdb">IE</country><country mxw-id="DS549799625" load-source="docdb">IS</country><country mxw-id="DS549782412" load-source="docdb">IT</country><country mxw-id="DS549799626" load-source="docdb">LI</country><country mxw-id="DS549782421" load-source="docdb">LT</country><country mxw-id="DS549874653" load-source="docdb">LU</country><country mxw-id="DS549782422" load-source="docdb">LV</country><country mxw-id="DS549782423" load-source="docdb">MC</country><country mxw-id="DS549874658" load-source="docdb">MT</country><country mxw-id="DS549870792" load-source="docdb">NL</country><country mxw-id="DS549867957" load-source="docdb">NO</country><country mxw-id="DS549870793" load-source="docdb">PL</country><country mxw-id="DS549782424" load-source="docdb">PT</country><country mxw-id="DS549890203" load-source="docdb">RO</country><country mxw-id="DS549870798" load-source="docdb">SE</country><country mxw-id="DS549783541" load-source="docdb">SI</country><country mxw-id="DS549867962" load-source="docdb">SK</country><country mxw-id="DS549874659" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><description mxw-id="PDES63960615" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001"><b>FIELD OF THE INVENTION</b></heading><p id="p0001" num="0001">The present invention relates generally to detection of occult blood from samples of the gastrointestinal (GI) tract. The present invention provides a method for simultaneous detection of hemoglobin and transferrin, using kcal samples. The method of the present invention provides a basis for a differential diagnosis of bleeding from the upper GI tract versus the lower GI tract.</p><heading id="h0002"><b>BACKGROUND OF THE INVENTION</b></heading><p id="p0002" num="0002">Fecal occult blood ("FOB") is a good indicator for monitoring bleeding from the gastrointestinal (GI) system. Since it may take several years for some colon polyps to transform into colorectal cancers, the detection of bleeding colon polyps is an effective way to screen for colorectal cancer at an early stage. The implementation of a procedure to screen for occult blood in fecal samples for adults of 50 years or older has reduced the incidences of colorectal cancer by 20% and mortality by 30%.</p><p id="p0003" num="0003">Currently available FOB tests include a chemical test that detects hemoglobin metabolites in fecal samples. The test employs an oxidizable substrate (such as guaiac) that produces a colored product in the presence of peroxide and hemoglobin. Since most animal heme molecules, plant ingredients and common vitamins can also catalyze the hydrogen peroxide reaction, diet control is critical to specificity of this type of chemical test. A strict diet control poses a serious patient compliance problem. On average, a compliance rate of lower than 10% is not unusual. Further, chemical tests generally have a limited sensitivity. For example, a FOB test using guaiac as substrate has a test sensitivity of 50 µg/ml, with an improved version having a test sensitivity of 20 µg/ml.<!-- EPO <DP n="2"> --></p><p id="p0004" num="0004">A sandwich immunoassay for hemoglobin has been developed, which provides improved test sensitivity and specificity as compared to chemical tests. The need for diet control is also eliminated for such immunoassay.</p><p id="p0005" num="0005">Hemoglobin is a labile protein; it degrades rapidly in human GI system. Hemoglobin is also susceptible to degradation during shipping and storage after fecal samples are collected. All these sample degradation problems affect the test accuracy of hemoglobin assays.</p><p id="p0006" num="0006">Transferrin is another biomarker for delecting fecal occult blood. In normal human blood the concentrations of transferrin and hemoglobin are 3 mg/ml and 150 mg/ml, respectively. On the other hand, the hemoglobin versus tranferrin ratio in fecal samples is approximately 5, which is much lower than the ratio (approximately 50) in blood. This observation indicates that transferrin is about 10 times more stable than hemoglobin in the GI tract. It has been reported that certain diseases may affect the levels of transferrin in blood and fecal samples to the extent that an FOB test based on transferrin alone may produce false negative results. A combination test for detecting both hemoglobin and transferrin may improve test sensitivity without sacrificing test specificity.</p><p id="p0007" num="0007">Another challenge for developing an FOB assay is that very few automated analyzers currently on the market can handle fecal samples. Therefore, a rapid onsite FOB test is desirable and in demand.</p><p id="p0008" num="0008"><patcit id="pcit0001" dnum="EP1256802A"><text>EP1256802</text></patcit> describes a feces occult blood test in which hemoglobin and/or transferrin are used as markers for feces occult blood.</p><p id="p0009" num="0009"><nplcit id="ncit0001" npl-type="s"><text>Chiang CH et al. "A,Comparative Study of Three Fecal Occult Blood Tests in Upper Gastrointestinal Bleeding". Kaohsiung J Med Sci May 2006;22:223-227</text></nplcit> describes a comparative study assessing the performance characteristics of three different occult blood tests (the o-toluidine test; the OC-Hemodia test; and the immunochromatographic Quick Chaser Occult Blood test) in cases of upper gastrointestinal bleeding.</p><p id="p0010" num="0010"><nplcit id="ncit0002" npl-type="s"><text>Miyoshi H et al. "Immunological Determination of Fecal Hemoglobin and Transferrin Levels: A Comparison with Other Fecal Occult Blood Tests", American Gournal of Gastroenterology 1992; 87:67-73</text></nplcit> describes a comparison of an occult fecal blood test comprising detection of hemoglobin and transferrin as with another fecal occult blood test (FECA-EIA) and two chemical tests (guaiac and Hemoccult) on three groups of patients comprising a control group, patients with colon cancer, and patients with polyps.</p><p id="p0011" num="0011"><nplcit id="ncit0003" npl-type="s"><text>Uchida K et al. "Immunochemical detection of human blood in feces". Clinica Chimica Acta 1990;189:267-274</text></nplcit> describes an immunochemical test for fecal occult blood utilizing an enzyme-linked immunosorbent assay of human hemoglobin and transferrin simultaneously.</p><p id="p0012" num="0012"><nplcit id="ncit0004" npl-type="s"><text>Miyoshi H et al, "Clinical study of a new fecal occult blood test using a combination assay of hemoglobin and transferrin", Gastroenterologia Japonica 1991;28:151-156</text></nplcit> describes a study on the applicability of a simultaneous hemoglobin and transferrin fecal occult blood test.<!-- EPO <DP n="3"> --></p><p id="p0013" num="0013"><nplcit id="ncit0005" npl-type="s"><text>Lee EW et al, "Differential Diagnosis of Gastrointestinal Bleeding", Techniques in Vascular and Interventional Radiology 2005;7:112-122</text></nplcit> is a review of the many causes of gastrointestinal bleeding and of strategies for rendering a specific diagnosis.</p><heading id="h0003"><b>SUMMARY OF THE INVENTION</b></heading><p id="p0014" num="0014">As described herein with reference to the claims, the present invetnion provides a method of differential diagnosis of bleeding from the upper GI tract versus the lower GI tract, comprising detecting transferrin and hemoglobin in a fecal sample using a lateral flow immunoassay device, and comparing the amounts of transferrin and hemoglobin detected with respective predetermined values of transferrin and hemoglobin, wherein the detection result is indicative of bleeding from the lower GI tract when the amount of transferrin is above a predetermined value for transferrin and the amount of hemoglobin is also above a predetermined value for hemoglobin, and wherein the detection result is indicative of bleeding from the upper GI tract when the amount of transferrin is above a predetermined value for transferrin and the amount of hemoglobin is below a predetermined value for hemoglobin, thereby making a differential diagnosis of bleeding from the upper GI tract versus the lower GI tract.</p><p id="p0015" num="0015">In an embodiment, said device comprises a test strip comprising: a sample site for applying a GI sample; a conjugate site downstream of said sample site, wherein a labeled anti-transferrin antibody and a labeled anti-hemoglobin antibody are deposited at said conjugate site; a test zone downstream of said conjugate site, wherein said test zone comprises two separate sites, one of which is immobilized with an anti-transferrin antibody, and the other is labeled immobilized with an anti-hemoglobin antibody; and a control site wherein a control antibody is immobilized thereto.</p><p id="p0016" num="0016">In another embodiment, said device comprises two test strips, wherein a first strip comprises: a sample site for applying a GI sample; a conjugate site downstream of said sample site, wherein a labeled anti-transferrin antibody is deposited at said conjugate site; a test zone downstream of said conjugate site, wherein said test zone comprises a test site wherein an anti-transferrin antibody is immobilized; a control site wherein a control antibody is immobilized thereto; and wherein a second strip comprises: a sample site for applying a GI sample; a conjugate site downstream of said sample site, wherein a labeled anti-hemoglobin antibody is deposited at said conjugate<!-- EPO <DP n="4"> --> site; a test zone downstream of said conjugate site, wherein said test zone comprises a test site wherein an anti-hemoglobin antibody is immobolized; and a control site wherein a control antibody is immobilized thereto.</p><p id="p0017" num="0017">In an aspect of the invention, the test strip may comprise a test membrane made of nitrocellulose.</p><p id="p0018" num="0018">In another aspect of the invetnion, said labeled anti-transferrin antibody and said labeled anti-hemoglobin antibody are both antibodies conjugated to gold particles.</p><p id="p0019" num="0019">A further embodiment of the invention comprises use of a lateral flow immunoassay device in any of the methods of the invention.</p><heading id="h0004"><b>BRIEF DESCRIPTION OF THE DRAWINGS</b></heading><p id="p0020" num="0020"><ul><li><figref idrefs="f0001"><b>Figure 1</b></figref> is a fecal sample collection device. The device contains a small screw cap, a large cap with stick and a vial with storage buffer. A user will unscrew the large cap with the brush from the vial, stabbing a fecal sample multi-times at different locations; insert the brush back into vial with storage buffer and tighten the screw. The fecal material collected on the brush will then be re-suspended into storage buffer and ready for testing. When a test operator receives the vial, the operator only needs to unscrew the small cap and squeeze the sample solution directly onto test device.</li><li><figref idrefs="f0002"><b>Figure 2</b></figref> is a top view of the test membrane for a combination sandwich immunoassay for transferrin and hemoglobin. The test strip includes an absorption pad (1), nitrocellulose membrane (2), a control line (3), two test lines for transferrin and hemoglobin, respectively (4), a marked line for maximum liquid level (8) and a sample pad (6).<!-- EPO <DP n="5"> --></li><li><figref idrefs="f0002"><b>Figure 3</b></figref> is a cross section of the same strip where item 7 is a plastic backing and item 5 is a gold-antibody conjugate pad underneath a label.</li><li><figref idrefs="f0002"><b>Figure 4</b></figref> illustrates three possible versions for a positive result of the presence of blood in the fecal sample.</li><li><figref idrefs="f0002"><b>Figure 5</b></figref> illustrates a negative result with the combination test.</li><li><figref idrefs="f0002"><b>Figure 6</b></figref> shows that in the absence of a colored control line the test result is invalid.</li></ul></p><heading id="h0005"><b>DETAILED DESCRIPTION OF THE INVENTION</b></heading><p id="p0021" num="0021">The present invention provides a sandwich immunoassay method and device that can detect bleeding from the entire GI system, and can support a differential diagnosis of upper GI bleeding versus lower GI bleeding. The immunoassay involves simultaneous detection of hemoglobin and transferrin. The immunoassay may utilize GI samples as well as samples of body fluids suspected of containing occult blood.</p><p id="p0022" num="0022">The present invention is based, at least in part, on the recognition of the difference in stability between transferrin and hemoglobin as occult blood markers. In most upper GI bleeding cases, hemoglobin is completely destroyed by gastric acids and proteases from the stomach, intestine and bacteria. Transferrin, on the other hand, can survive passage through the GI tract. In tests conducted leading to the present invention, it has been found that in patients clinically diagnosed to suffer from an upper GI disorder, transferrin tested positive and hemoglobin tested negative in fecal samples as well as in vomit and liquid samples collected from the upper GI. Additionally, it has been found that in patients clinically diagnosed to suffer from a lower GI disorder where hemoglobin tested positive in fecal samples, transferrin also tested positive.</p><p id="p0023" num="0023">Accordingly, the application provides a method for detecting transferrin in upper GI samples to aid in the diagnosis of bleeding from the upper GI tract. The present invention provides a method for the simultaneous detection of hemoglobin and transferrin in fecal samples to aid in the diagnosis of bleeding from the entire GI tract, and to differentiate bleeding in the<!-- EPO <DP n="6"> --> upper GI tract from bleeding in the lower GI tract. Test devices are provided for performing the methods of the present invention.</p><p id="p0024" num="0024">The term "upper GI tract" refers to the upper portion of the GI tract and includes the mouth, pharynx, esophagus, stomach and dodeneum. On the other hand, the "lower GI tract" refers to the lower portion of the GI tract and consists of the intestines, colon, rectum and anus. Although applicable to diagnosis of bleeding from any parts of the GI tract, the presently claimed method is particularly useful for diagnosis of bleeding from the upper GI tract, whereas currently there is no reliable fecal strip-based test available in clinical setting.</p><p id="p0025" num="0025">The term "GI sample" refers to a sample or collection of solid or liquid materials released or secreted from the GI tract, such as feces and vomits (an upper GI sample), as well as solid or liquid materials collected from the GI tract, such as gastric materials retrieved from the stomach (also an upper GI sample). The raw materials collected are typically suspended or diluted in a buffer (such as saline solutions) before use in an immunoassay.</p><p id="p0026" num="0026">By "fecal sample" is meant a sample collected following defecation, which is typically mixed subsequently with a solution, which is suitable for use in an immunoassay.</p><p id="p0027" num="0027">The term "diagnosis" or "diagnosing" should be understood to mean determination of the likelihood of the bleeding being associated with upper or lower GI tract. For example, when transferrin is tested positive in a fecal sample whereas hemoglobin is tested negative, then bleeding is likely to be from the upper GI tract. When both hemoglobin and transferrin are tested to be "positive" in a fecal sample, then bleeding is likely to be from the lower GI tract. Diagnosis can also be made based on the relative ratio of hemoglobin to transferrin in a fecal sample - the higher the ratio (or the closer the ratio is to the ratio in blood), the more likely the test subject has lower GI tract bleeding. Conversely, the lower the ratio, the more likely the test subject has upper GI tract bleeding.</p><p id="p0028" num="0028">The terms "positive" and "negative" refer to values of a test analyte to be above and below a predetermined value (base or threshold concentration), respectively. The terms also refer to the presence and absence, respectively, of a detectable or visible signal.<!-- EPO <DP n="7"> --></p><p id="p0029" num="0029">The "predetermined value" for an analyte refers to the base or threshold concentration of an analyte in normal individuals; and if the value of the analyte is significantly above such predetermined value, it is indicative of abnormality such as bleeding. The predetermined value for an analyte may vary depending on the format of the assay, and the specific reagents employed in the assay (e.g., the particular antibodies used), but can be determined and set by those skilled in the art by assessing the concentration of the analyte in normal individuals relative to control samples containing known amounts of the analyte.</p><p id="p0030" num="0030">Hemoglobin and transferrin in GI samples can be detected by a variety of immunoassays using antibodies specific for hemoglobin and transferrin.</p><p id="p0031" num="0031">By "antibody" is meant a monoclonal or polyclonal antibody. Both full-length antibody molecules and antigen-binding fragments of full-length antibodies can be employed.</p><p id="p0032" num="0032">In a specific embodiment, the detection is achieved by employing a sandwich immunoassay, which involves the use of a pair of antibodies specific for the analyte to be detected. The antibodies in the pair are complementary to each other-that is, the antibodies bind to different epitopes of the analyte and permits the formation of the sandwich complex: antibody 1-analyte-antibody 2. Typically, one antibody of the antibody pair is immobilized on a solid material (also referred to as "capture antibody"), for example, on a nitrocellulose membrane, a microtiter plate, or beads, whereas the other antibody of the pair is conjugated with a label or a signal generator. To perform the assay, a sample containing the analyte is mixed with the antibody conjugate to form a reaction mixture, and the reaction mixture is then applied to the solid material, permitting the capture antibody to capture of complex formed between the analyte and antibody conjugate. Alternatively, a sample containing the analyte is applied to the solid material and is captured by the capture antibody bound to the solid material. A conjugate antibody is then added to form a sandwich complex between the capture antibody, the analyte and the conjugate antibody. Unbound materials are washed away, and a signal is developed and read, either visually or instrumentally.<!-- EPO <DP n="8"> --></p><p id="p0033" num="0033">According to the present invention, an antibody can be conjugated to a "label", "signal generator" or "signal generating element" (hence also referred to as a "labeled antibody"), which refers to an entity that can embody a number of different forms: enzymes and their resultant effects on a substrate, colloidal metal particles, and latex with dye incorporated, and dye particles. An enzyme can react on a substrate to produce a product that is sensible, for example, by color of absorption (e.g., ultraviolet, visible, infrared), or by fluorescence.</p><p id="p0034" num="0034">Metal particles can be employed as signal generator, which can be made of platinum, gold, silver, selenium, or copper or any other of metal compounds which exhibit characteristic colors. The metal particles suitable for use in the present invention can be prepared by conventional methodologies. For example, the preparation of gold sol particles is described <nplcit id="ncit0006" npl-type="s"><text>Frens, Nature 241: 20-22 (1973</text></nplcit>). Additionally, the metal particles may be metal or metal compounds or polymer nuclei coated with metals or metal compounds, as described in <patcit id="pcit0002" dnum="US4313734A"><text>U.S. Patent No. 4,313,734</text></patcit>.</p><p id="p0035" num="0035">The metal particles may be gold particles of a size in the range of 5nm to 100nm, preferably in the range of 8nm to 60nm, and more preferably in the range of 10 to 40nm.</p><p id="p0036" num="0036">A desired antibody can be coupled to metal particles using conventional techniques, including but not limited to covalent coupling and hydrophobic bonding. Additionally, the antibody can be conjugated to the particles using a biotin/streptoavidin linkage.</p><p id="p0037" num="0037">Additionally, other solid phase particles suitable for use in producing particles conjugated with antibodies include, for example, particles of color latex, carbon black and dye particles.</p><p id="p0038" num="0038">The detection of hemoglobin and transferrin is achieved by employing a lateral flow immunoassay. A device illustrating the working of such an assay is shown in <figref idrefs="f0002">Figures 2-3</figref>.</p><p id="p0039" num="0039">The immunoassay lateral flow test device generally includes a test strip having a backing support 7, which can be made of plastic, cardboard, or any other rigid material, and preferably made of a plastic material. On top of the backing support 7, is a testing membrane 2, preferably made of a nitrocellulose membrane,<!-- EPO <DP n="9"> --> which may be affixed to the support 7. On the top surface of the testing membrane 2 are the areas to which the appropriate reagents are affixed, including a test area 4 comprising two separate test sites, with an anti-transferrin antibody immobilized to one site, and an anti-hemoglobin antibody immobilized to the other site. The testing membrane also has a control zone 3 having a control antibody immobilized thereto.</p><p id="p0040" num="0040">The test strip also contains a sample site for applying a diluted sample to the test strip, and a conjugate site downstream of the sample site. Generally, an absorbent sample pad 6 is placed at the sample site, and is placed in contact with a conjugate pad 5 at the conjugate site. The conjugate pad is typically placed on top of and in direct contact with one end portion of the testing membrane 2, and contains an anti-transferrin antibody conjugated with a signal generating element and an anti-hemoglobin antibody also conjugated with a signal generating element. At the other end of the test membrane 2 and on top of the testing membrane is placed an absorption pad 1. When a GI sample is applied to the sample pad 6, the sample will migrate towards the absorption pad 1 and get transferred to the test membrane 2.</p><p id="p0041" num="0041">The conjugate site is a pad containing gold particles conjugated with an antitransferrin antibody and gold particles conjugated with an anti-hemoglobin antibody. Gold particles conjugated with an antibody can be prepared as described above, and are preferably of a size in the range of 5nm to 100nm, more preferably in the range of 8nm to 60nm, and even more preferably in the range of 10 to 40nm.</p><p id="p0042" num="0042">As described above, other metals (such as platinum, silver, selenium, and copper) can also be used to produce metal particles conjugated with an antibody. Additionally, other solid phase particles suitable for use in producing particles conjugated with antibodies include, for example, particles of color latex, carbon black and dye particles.</p><p id="p0043" num="0043">The gold antibody conjugates are deposited and dried on a absorbent pad 5, which is placed downstream from the sample pad 6 where the sample is applied. Alternatively gold particles conjugated with a desired antibody are dried and deposited directly on the end of test membrane 2 adjacent and downstream of the sample pad 6.<!-- EPO <DP n="10"> --></p><p id="p0044" num="0044">The lateral flow immunoassay device illustrated in <figref idrefs="f0002">Figures 2-3</figref> can also include a casing, in which the test strip is placed. The casing can take a number of different forms that permit the application of the sample to the sample pad, permit the sample to migrate along the test membrane by lateral flow, and permit the viewing the results that occur in the test and control zones.</p><p id="p0045" num="0045"><figref idrefs="f0002">Figures 2-5</figref> illustrate the assembly of a test strip for a simultaneous detection of transferrin and hemoglobin based on sandwich immunoassays. A GI sample is applied onto the sample pad 6, and the liquid in the sample migrates by capillary action towards the absorption pad 1. When the liquid sample reaches the gold conjugate pad 5, the gold-anti-transferrin conjugate and gold-anti-hemoglobin conjugate within the gold conjugate pad 5 are resuspended in the liquid, and the resulting complexes, i.e., gold-anti-transferin-transferin and gold-anti-hemoglobin-hemoglobin, then move onto the membrane 2. When the liquid sample containing the complexes reaches the test zone 4, it will react with the anti-transferrin and anti-hemoglobin antibodies immobilized on their respective test line. In the absence of a specified analyte, there will be no formation of a sandwich complex, i.e., gold conjugated antibody - analyte - immobilized antibody, and the test line zone 4 will remain colorless as shown in <figref idrefs="f0002"><b>Figure 5</b></figref><b>.</b> In the presence of the analyte, the sandwich complex will form on their specific test lines as illustrated in <figref idrefs="f0002"><b>Figure 4</b></figref><b>.</b> When the gold-antibody conjugate, which is always in excess of the antigens (transferrin and hemoglobin) present in the sample, moves down the membrane and reaches the control line 3, the immobilized goat-anti-mouse IgG will react with the gold-antibody conjugate to form a color line in the control zone 3. The control zone serves as an indicator to assure the liquid movement of the device. The absence of a colored control line as shown in <figref idrefs="f0002"><b>Figure 6</b></figref> indicates a failed test.</p><p id="p0046" num="0046">It should be noted that <figref idrefs="f0002"><b>Figures 2-5</b></figref> are merely illustrations of one test device for a simultaneous detection of transferrin and hemoglobin, and are not intended to limit the present invention. For example, those skilled in the art can readily appreciate that the two sites within the test area 4 can also be placed separately (e.g., juxtaposed) at the same position along the lateral flow direction. Furthermore, the test device can be made to contain two separate test strips, one for testing hemoglobin (including a sample pad, a gold-conjugate pad, a test area<!-- EPO <DP n="11"> --> containing only anti-hemoglobin antibodies and a control area), and the other one for testing transferrin (including a sample pad, a gold-conjugate pad, a test area containing only anti-transferrin antibodies and a control area). With such a device, a user can also have the option to apply the sample to only one of the two test strips, depending on the need and circumstances for the testing.</p><p id="p0047" num="0047">This invention is further illustrated by the following examples, which are not to be construed in any way as imposing limitations upon the scope thereof. The terms and expressions which have been employed in the present disclosure are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof. It is to be understood that various modifications are possible within the scope of the invention.</p><heading id="h0006"><u><b>Example</b> 1</u></heading><heading id="h0007"><b>Preparation of Monoclonal Antibodies Against Hemoglobin and Transferrin</b></heading><p id="p0048" num="0048">BALB/c mice were immunized with purified human hemoglobin for three months to induce antibody production. After the antiserum titer reached a desired level, mice were sacrificed. Isolated spleen cells were used for hybridoma fusion with cells of the SP20 line. A pair of hybridoma cell lines, Hb10E11G12 and Hb2H11D12, were isolated and used to produce ascites fluid from BALB/c mice. Anti-hemoglobin antibodies were then purified from ascites fluid and used in sandwich immunoassays for detecting hemoglobin.</p><p id="p0049" num="0049">Anti-transferrin antibodies were produced following a similar procedure. A matching pair of hybridoma cell lines, TF31E5G1 and TF32A2G 1, were isolated and used in sandwich immunoassays for detecting transferrin.</p><heading id="h0008"><b><u>Example 2</u></b></heading><heading id="h0009"><b>Preparation of Gold Particles and Antibody Conjugate</b></heading><p id="p0050" num="0050">Antibody-conjugated gold particles were chosen as the detection means in a lateral flow immunoassay. A colloidal gold particle solution was prepared by the<!-- EPO <DP n="12"> --> reduction of gold chloride with sodium citrate at the boiling point of the mixture. A pink to purple colored colloidal gold solution with gold particles of a size around 10 to 40 nm was used in preparing gold-antibody conjugates. One of the paired antibodies was used to coat gold particles at a pH value close to the pI value of the antibody. BSA and PEG were used to block the leftover binding sites on the gold particles, to wash and concentrate the conjugated gold-antibody solution. A pad, typically a pad made of fiber glass or rayon, was submerged in the conjugated gold-antibody solution and was dried afterwards so that the gold-antibody conjugates were deposited in the pad.</p><heading id="h0010"><b><u>Example 3</u></b></heading><heading id="h0011"><b>Test lines and Control line</b></heading><p id="p0051" num="0051">- A nitrocellulose membrane with an average pore size of around 5 to 20 µm was chosen as the test membrane. The selected antibodies were immobilized on the membrane at the specified test line zones. A control line zone was also included in test membrane to assure the physical performance of the test, where a goat anti-mouse-IgG antibody was immobilized.</p><heading id="h0012"><b><u>Example 4</u></b></heading><heading id="h0013"><b>Assembly and Performance of a Test Strip</b></heading><p id="p0052" num="0052"><figref idrefs="f0002"><b>Figures 2-3</b></figref> illustrate the assembly of a test strip for simultaneous detection of transferrin and hemoglobin based on sandwich immunoassays.</p><heading id="h0014"><b><u>Example 5</u></b></heading><heading id="h0015"><b>Detection of Transferrin</b></heading><p id="p0053" num="0053">Dilution buffer solutions (typically PBS buffers) in fecal sample collectors were spiked (supplemented with transferrin) to a final concentration of transferrin at 10, 20, 40, 50, 75, and 100 ng/ml, respectively. Three random fecal samples from normal individuals were collected and inserted into collection devices containing transferrin-spiked buffer solutions. These three samples were tested using the test device shown in <figref idrefs="f0002"><b>Figures 2-3</b></figref><b>.</b> The results are shown in <b>Table 1.</b> All sample solutions<!-- EPO <DP n="13"> --> with a transferrin level above the cutoff value of 30 ng/ml showed a positive signal, and all samples with transferrin below the cutoff value showed negative results.
<tables id="tabl0001" num="0001"><table frame="all"><title><b>Table 1</b></title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="31mm"/><colspec colnum="2" colname="col2" colwidth="19mm"/><colspec colnum="3" colname="col3" colwidth="19mm"/><colspec colnum="4" colname="col4" colwidth="19mm"/><thead><row><entry valign="top">Transferrin (ng/ml)</entry><entry valign="top">Sample 1</entry><entry valign="top">Sample 2</entry><entry valign="top">Sample 3</entry></row></thead><tbody><row><entry>10</entry><entry>-</entry><entry>-</entry><entry>-</entry></row><row><entry>20</entry><entry>-</entry><entry>-</entry><entry>-</entry></row><row><entry>40</entry><entry>+</entry><entry>+</entry><entry>+</entry></row><row><entry>50</entry><entry>+</entry><entry>+</entry><entry>+</entry></row><row><entry>75</entry><entry>+</entry><entry>+</entry><entry>+</entry></row><row><entry>100</entry><entry>+</entry><entry>+</entry><entry>+</entry></row></tbody></tgroup></table></tables></p><heading id="h0016"><b><u>Example 6</u></b></heading><heading id="h0017"><b>Detection of Hemoglobin</b></heading><p id="p0054" num="0054">Dilution buffer solutions in fecal sample collectors were spiked to a final concentration of hemoglobin at 0.05, 0.1, 0.2, 0.5, 20, and 2000 µg/ml, respectively. Three random fecal samples from normal individuals were collected and inserted into the collection devices containing hemoglobin spiked buffer solutions. These three samples were tested using the test device shown in <figref idrefs="f0002"><b>Figures 2-3</b></figref><b>.</b> The results are shown in <b>Table 2.</b> All sample solutions with a hemoglobin level above the cutoff value of 0.2 µg/ml showed a positive signal and all samples with hemoglobin below the cutoff value showed negative results.
<tables id="tabl0002" num="0002"><table frame="all"><title><b>Table 2</b></title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="34mm"/><colspec colnum="2" colname="col2" colwidth="19mm"/><colspec colnum="3" colname="col3" colwidth="19mm"/><colspec colnum="4" colname="col4" colwidth="19mm"/><thead><row><entry valign="top">Hemoglobin (µg/ml)</entry><entry valign="top">Sample 1</entry><entry valign="top">Sample 2</entry><entry valign="top">Sample 3</entry></row></thead><tbody><row><entry>0.05</entry><entry>-</entry><entry>-</entry><entry>-</entry></row><row><entry>0.1</entry><entry>-</entry><entry>-</entry><entry>-</entry></row><row><entry>0.2</entry><entry>+</entry><entry>+</entry><entry>+</entry></row><row><entry>0.5</entry><entry>+</entry><entry>+</entry><entry>+</entry></row><row><entry>20</entry><entry>+</entry><entry>+</entry><entry>+</entry></row><!-- EPO <DP n="14"> --><row><entry>2000</entry><entry>+</entry><entry>+</entry><entry>+</entry></row></tbody></tgroup></table></tables></p><heading id="h0018"><b><u>Example 7</u></b></heading><heading id="h0019"><b>Differential Diagnosis of Upper GI Bleeding Using Fecal Samples</b></heading><p id="p0055" num="0055">The hemoglobin and transferrin combination test and a guaiac test were used to assay fecal samples from patients experiencing clinically confirmed stomach problems identified in <b>Table 3.</b> The results of the lateral flow sandwich immunoassay based on the anti-hemoglobin antibodies alone only detected 7 out of 62 cases as positive for fecal blood. The guaiac test, a chemical test that detects the peroxidase activity of heme, identified 25 cases. However, the lack of specificity of the guaiac test made the identification of these 25 cases questionable. On the other hand, the anti-transferrin antibodies identified 51 of 62 cases as positive for fecal blood. <b>Table 3</b> shows the results. Therefore, transferrin is a more sensitive marker for detection of upper GI bleeding. The combination transferrin and hemoglobin immunoassay permits a differential diagnosis of upper GI bleeding.
<tables id="tabl0003" num="0003"><table frame="all"><title><b>Table 3</b></title><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="31mm"/><colspec colnum="2" colname="col2" colwidth="22mm"/><colspec colnum="3" colname="col3" colwidth="29mm"/><colspec colnum="4" colname="col4" colwidth="22mm"/><colspec colnum="5" colname="col5" colwidth="27mm"/><thead><row><entry valign="top">Symptom</entry><entry valign="top">Total Cases</entry><entry valign="top">Hemoglobin Test</entry><entry valign="top">Guaia Test</entry><entry valign="top">Transferrin Test</entry></row></thead><tbody><row><entry>Stomach Bleeding</entry><entry>18</entry><entry>6+</entry><entry>10+</entry><entry>17+</entry></row><row><entry>Peptic Ulcer</entry><entry>5</entry><entry>0+</entry><entry>2+</entry><entry>4+</entry></row><row><entry>Ulcer</entry><entry>14</entry><entry>1+</entry><entry>5+</entry><entry>12+</entry></row><row><entry>Operation</entry><entry>9</entry><entry>0+</entry><entry>4+</entry><entry>6+</entry></row><row><entry>Gastritis</entry><entry>11</entry><entry>0+</entry><entry>2+</entry><entry>9+</entry></row><row><entry>Polyp</entry><entry>5</entry><entry>0+</entry><entry>2+</entry><entry>3+</entry></row></tbody></tgroup></table></tables></p><heading id="h0020"><b><u>Example 8</u></b></heading><heading id="h0021"><b>Diagnosis of Upper GI Bleeding Using Vomit And Liquid Samples From Upper GI System</b></heading><p id="p0056" num="0056">In this example, seven vomit and stomach fluid samples from clinically confirmed upper GI patients were tested again with the hemoglobin/transferrin combination test device and the guiac test. Results in <b>Table 4</b> show that all samples<!-- EPO <DP n="15"> --> were tested negative in the guiac test, and in the immunoassay for hemoglobin as the marker. On the other hand, Transferrin tested positive for all samples, indicating occult blood from these upper GI samples.
<tables id="tabl0004" num="0004"><table frame="all"><title><b>Table 4</b></title><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="24mm"/><colspec colnum="2" colname="col2" colwidth="14mm"/><colspec colnum="3" colname="col3" colwidth="22mm"/><colspec colnum="4" colname="col4" colwidth="20mm"/><colspec colnum="5" colname="col5" colwidth="22mm"/><thead><row><entry valign="top">Sample</entry><entry valign="top">No.</entry><entry valign="top">Hemoglobin</entry><entry valign="top">Transferrin</entry><entry valign="top">Guaiac test</entry></row></thead><tbody><row><entry>Vomit</entry><entry>4</entry><entry>All negative</entry><entry>All positive</entry><entry>All negative</entry></row><row><entry>Stomach fluid</entry><entry>3</entry><entry>All negative</entry><entry>All positive</entry><entry>All negative</entry></row></tbody></tgroup></table></tables></p><heading id="h0022"><b><u>Example 9</u></b></heading><heading id="h0023"><b>Diagnosis of Lower GI Bleeding Using Fecal Samples</b></heading><p id="p0057" num="0057"><b>Table 5</b> shows results from a testing of 45 fecal samples from patients with clinically confirmed lower GI disorders. Forty cases where hemoglobin tested positive, transferrin also tested positive. The results also demonstrate that the hemoglobin test and the transferrin test can complement each other to increase the test sensitivity of FOB detection. Either test alone missed a few positive samples, whereas the combination test (which determines FOB based on a positive result from either test) had detected all but two positive samples. The results further demonstrate that the hemoglobin and the transferrin tests are more sensitive than the guaiac test.
<tables id="tabl0005" num="0005"><table frame="all"><title><b>Table 5</b></title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="15mm"/><colspec colnum="2" colname="col2" colwidth="14mm"/><colspec colnum="3" colname="col3" colwidth="29mm"/><colspec colnum="4" colname="col4" colwidth="27mm"/><colspec colnum="5" colname="col5" colwidth="26mm"/><colspec colnum="6" colname="col6" colwidth="22mm"/><thead><row><entry valign="top">Sample</entry><entry valign="top">No.</entry><entry valign="top">Hemoglobin Test</entry><entry valign="top">Transferrin Test</entry><entry valign="top">Combined Test</entry><entry valign="top">Guaiac Test</entry></row></thead><tbody><row><entry>Feces</entry><entry>45</entry><entry>40 +/5 -</entry><entry>42 +/3 -</entry><entry>43 +/2 -</entry><entry>16 +/29 -</entry></row></tbody></tgroup></table></tables></p></description><claims mxw-id="PCLM56984582" lang="DE" load-source="patent-office"><!-- EPO <DP n="18"> --><claim id="c-de-01-0001" num="0001"><claim-text>Verfahren zur Differentialdiagnose von Blutungen aus dem oberen Gastrointestinaltrakt gegenüber dem unteren Gastrointestinaltrakt, welches aufweist, Transferrin und Hämoglobin in einer Stuhlprobe unter Verwendung einer Lateralfluss-Immunoassay-Vorrichtung zu detektieren und die detektierten Mengen von Transferrin und Hämoglobin mit jeweiligen vorbestimmten Werten für Transferrin und Hämoglobin zu vergleichen, wobei das Detektionsergebnis eine Blutung aus dem unteren Gastrointestinaltrakt anzeigt, wenn die Menge an Transferrin über einen vorbestimmten Wert für Transferrin ist, und wenn die Menge an Hämoglobin auch über einen vorbestimmten Wert für Hämoglobin ist, und wobei das Detektionsergebnis eine Blutung aus dem oberen Gastrointestinaltrakt anzeigt, wenn die Menge an Transferrin über einen vorbestimmten Wert für Transferrin ist und die Menge an Hämoglobin unter einen vorbestimmten für Hämoglobin ist, wodurch eine Differentialdiagnose zwischen einer Blutung aus dem oberen Gastrointestinaltrakt oder aus dem unteren Gastrointestinaltrakt gemacht wird.</claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Verfahren nach Anspruch 1, wobei die Vorrichtung einen Teststreifen aufweist, der Folgendes aufweist:
<claim-text>(1) eine Probenstelle zum Aufbringen einer Probe aus dem Gastrointestinaltrakt;</claim-text>
<claim-text>(2) eine Konjugatstelle stromabwärts der Probenstelle, wobei ein gelabelter Anti-Transferrin-Antikörper und ein gelabelter Anti-Hämoglobin-Antikörper an der Konjugatstelle abgelagert sind;</claim-text>
<claim-text>(3) eine Testzone stromabwärts der Konjugatstelle, wobei die Testzone zwei getrennte Stellen aufweist, wobei eine davon mit einem Anti-Transferrin-Antikörper immobilisiert bzw. fixiert ist, und wobei die andere mit einem Anti-Hämoglobin-Antikörper fixiert ist;</claim-text>
<claim-text>(4) eine Steuerstelle, wo einer Steuer-Antikörper immobilisiert bzw. fixiert ist.</claim-text><!-- EPO <DP n="19"> --></claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Verfahren nach Anspruch 1, wobei die Vorrichtung zwei Teststreifen aufweist, wobei ein erster Streifen Folgendes aufweist:
<claim-text>(1) eine Probenstelle zum Aufbringen einer Probe aus dem Gastrointestinaltrakt;</claim-text>
<claim-text>(2) eine Konjugatstelle stromabwärts von der Probenstelle, wobei ein gelabelter Anti-Transferrin-Antikörper an der Konjugatstelle abgelagert ist;</claim-text>
<claim-text>(3) eine Testzone stromabwärts der Konjugatstelle, wobei die Testzone eine Teststelle aufweist, wo ein Anti-Transferrin-Antikörper immobilisiert bzw. fixiert ist;</claim-text>
<claim-text>(4) eine Steuerstelle, wo ein Steuer-Antikörper immobilisiert bzw. fixiert ist; und</claim-text>
wobei ein zweiter Streifen Folgendes aufweist:
<claim-text>(1) eine Probenstelle zum Aufbringen einer Probe aus einem Gastrointestinaltrakt;</claim-text>
<claim-text>(2) eine Konjugatstelle stromabwärts der Probenstelle, wobei ein gelabelter Anti-Hämoglobin-Antikörper an der Konjugatstelle abgelagert ist;</claim-text>
<claim-text>(3) eine Testzone stromabwärts der Konjugatstelle, wobei die Testzone eine Teststelle aufweist, wo ein Anti-Hämoglobin-Antikörper immobilisiert bzw. fixiert ist; und</claim-text>
<claim-text>(4) eine Steuerstelle, wo ein Steuer-Antikörper fixiert ist.</claim-text></claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Verfahren nach Anspruch 2 oder 3, wobei der Teststreifen eine Testmembran aufweist, die aus Nitro-Zellulose gemacht ist.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Verfahren nach Anspruch 2 oder 3, wobei der gelabelte Anti-Transferrin-Antikörper und der gelabelte Anti-Hämoglobin-Antikörper beide Antikörper sind, die mit Goldpartikeln konjugiert bzw. verbunden sind.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Verwendung einer Lateralfluss-Immunoassy-Vorrichtung in dem Verfahren nach einem der Ansprüche 1 bis 5.</claim-text></claim></claims><claims mxw-id="PCLM56984583" lang="EN" load-source="patent-office"><!-- EPO <DP n="16"> --><claim id="c-en-01-0001" num="0001"><claim-text>A method of differential diagnosis of bleeding from the upper GI tract versus the lower GI tract, comprising detecting transferrin and hemoglobin in a fecal sample using a lateral flow immunoassay device, and comparing the amounts of transferrin and hemoglobin detected with respective predetermined values of transferrin and hemoglobin, wherein the detection result is indicative of bleeding from the lower GI tract when the amount of transferrin is above a predetermined value for transferrin and the amount of hemoglobin is also above a predetermined value for hemoglobin, and wherein the detection result is indicative of bleeding from the upper GI tract when the amount of transferrin is above a predetermined value for transferrin and the amount of hemoglobin is below a predetermined value for hemoglobin, thereby making a differential diagnosis of bleeding from the upper GI tract versus the lower GI tract.</claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>The method of claim 1, wherein said device comprises a test strip comprising:
<claim-text>(1) a sample site for applying a GI sample;</claim-text>
<claim-text>(2) a conjugate site downstream of said sample site, wherein a labeled anti-transferrin antibody and a labeled anti-hemoglobin antibody are deposited at said conjugate site;</claim-text>
<claim-text>(3) a test zone downstream of said conjugate site, wherein said test zone comprises two separate sites, one of which is immobilized with an anti-transferrin antibody, and the other is labeled immobilized with an anti-hemoglobin antibody; and</claim-text>
<claim-text>(4) a control site wherein a control antibody is immobilized thereto.</claim-text></claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>The method of claim 1, wherein said device comprises two test strips, wherein a first strip comprises:
<claim-text>(1) a sample site for applying a GI sample;</claim-text>
<claim-text>(2) a conjugate site downstream of said sample site, wherein a labeled anti-transferrin antibody is deposited at said conjugate site;</claim-text>
<claim-text>(3) a test zone downstream of said conjugate site, wherein said test zone comprises a test site wherein an anti-transferrin antibody is immobilized;</claim-text>
<claim-text>(4) a control site wherein a control antibody is immobilized thereto; and</claim-text><!-- EPO <DP n="17"> -->
wherein a second strip comprises:
<claim-text>(1) a sample site for applying a GI sample;</claim-text>
<claim-text>(2) a conjugate site downstream of said sample site, wherein a labeled anti-hemoglobin antibody is deposited at said conjugate site;</claim-text>
<claim-text>(3) a test zone downstream of said conjugate site, wherein said test zone comprises a test site wherein an anti-hemoglobin antibody is immobolized; and</claim-text>
<claim-text>(4) a control site wherein a control antibody is immobilized thereto.</claim-text></claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>The method of claim 2 or 3, wherein said test strip comprises a test membrane made of nitrocellulose.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>The method of claim 2 or 3, wherein said labeled anti-transferrin antibody and said labeled anti-hemoglobin antibody are both antibodies conjugated to gold particles.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>Use of a lateral flow immunoassay device in the method of any of claims 1-5.</claim-text></claim></claims><claims mxw-id="PCLM56984584" lang="FR" load-source="patent-office"><!-- EPO <DP n="20"> --><claim id="c-fr-01-0001" num="0001"><claim-text>Procédé de diagnostic différentiel de saignements du tube digestif supérieur par rapport au tube digestif inférieur, comprenant la détection de transferrine et d'hémoglobine dans un échantillon de matières fécales en utilisant un dispositif de dosage immunologique à flux latéral, et la comparaison des quantités de transferrine et d'hémoglobine détectées à des valeurs prédéterminées respectives de transferrine et d'hémoglobine, dans lequel le résultat de la détection est indicatif de saignements provenant du tube digestif inférieur lorsque la quantité de transferrine est supérieure à une valeur prédéterminée pour la transferrine et la quantité d'hémoglobine est aussi supérieure à une valeur prédéterminée pour l'hémoglobine, et dans lequel le résultat de la détection est indicatif de saignements provenant du tube digestif supérieur lorsque la quantité de transferrine est supérieure à une valeur prédéterminée pour la transferrine et la quantité d'hémoglobine est inférieure à une valeur prédéterminée pour l'hémoglobine, réalisant par cela un diagnostic différentiel de saignements du tube digestif supérieur par rapport au tube digestif inférieur.</claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Procédé selon la revendication 1, dans lequel le dispositif comprend une bande de test comprenant :
<claim-text>(1) un site d'échantillon pour appliquer un échantillon provenant du tube digestif ;</claim-text>
<claim-text>(2) un site conjugué en aval du site d'échantillon, dans lequel un anticorps anti-transferrine marqué et un anticorps anti-hémoglobine marqué sont déposés au niveau du site conjugué ;</claim-text>
<claim-text>3) une zone de test en aval du site conjugué, la zone de test comprenant deux sites séparés, dont l'un est immobilisé avec un anticorps anti-transferrine, et l'autre est immobilisé marqué avec un anticorps anti-hémoglobine ; et<!-- EPO <DP n="21"> --></claim-text>
<claim-text>(4) un site de contrôle dans lequel un anticorps de contrôle est immobilisé.</claim-text></claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Procédé selon la revendication 1, dans lequel le dispositif comprend deux bandes de test, dans lequel la première bande comprend :
<claim-text>(1) un site d'échantillon pour appliquer un échantillon provenant du tube digestif ;</claim-text>
<claim-text>(2) un site conjugué en aval du site d'échantillon, dans lequel un anticorps anti-transferrine est déposé au niveau du site conjugué ;</claim-text>
<claim-text>(3) une zone de test en aval du site conjugué, la zone de test comprenant un site de test dans lequel un anticorps anti-transferrine est immobilisé ;</claim-text>
<claim-text>(4) un site de contrôle dans lequel un anticorps de contrôle est immobilisé ; et</claim-text>
dans lequel la deuxième bande comprend :
<claim-text>(1) un site d'échantillon pour appliquer un échantillon provenant du tube digestif ;</claim-text>
<claim-text>(2) un site conjugué en aval du site d'échantillon, dans lequel un anticorps anti-hémoglobine marqué est déposé au niveau du site conjugué ;</claim-text>
<claim-text>(3) une zone de test en aval du site conjugué, la zone de test comprenant un site de test dans lequel un anticorps anti-hémoglobine est immobilisé ; et</claim-text>
<claim-text>(4) un site de contrôle dans lequel un anticorps de contrôle est immobilisé.</claim-text></claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Procédé selon la revendication 2 ou 3, dans lequel la bande de test comprend une membrane de test en nitrocellulose.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Procédé selon la revendication 2 ou 3, dans lequel l'anticorps anti-transferrine marqué et l'anticorps anti-hémoglobine marqué sont tous les deux des anticorps conjugués à des particules d'or.<!-- EPO <DP n="22"> --></claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Utilisation d'un dispositif de dosage immunologique à flux latéral par le procédé de l'une quelconque des revendications 1 à 5.</claim-text></claim></claims><drawings mxw-id="PDW16671901" load-source="patent-office"><!-- EPO <DP n="23"> --><figure id="f0001" num="1A,1B"><img id="if0001" file="imgf0001.tif" wi="101" he="197" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="24"> --><figure id="f0002" num="2,3,4A,4B,4C,5,6"><img id="if0002" file="imgf0002.tif" wi="147" he="220" img-content="drawing" img-format="tif"/></figure></drawings><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
